Evidence map›Paper›PMID 41574312›Full record

ArticleBlood neoplasia2026

Extended long-term follow-up and the survival of Stop Imatinib study.

François-Xavier Mahon, Stéphanie Dulucq, Delphine Réa, Franck-Emmanuel Nicolini, Françoise Rigal-Huguet, Katerina Machova Polakova, Viviane Dubruille, Marie-Pierre Noel, Jean-Christophe Ianotto, Bruno Villemagne and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Road to treatment-free remission in chronic myeloid leukemia.International journal of hematology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

François-Xavier MahonDépartement d'Hématologie, Institut Bergonié, University of Bordeaux, INSERM, UMR1312, Bordeaux, France.
Stéphanie DulucqLaboratoire d'hématologie Centre Hospitalier Universitaire Bordeaux, University of Bordeaux, INSERM, UMR1312, Bordeaux Insitute of Oncology, Bordeaux, France.
Delphine RéaService d'Hématologie Adulte, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Franck-Emmanuel NicoliniService d'Hématologie & INSERM U590, Centre Leon Berard, Lyon, France.
Françoise Rigal-HuguetService d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Katerina Machova PolakovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Viviane DubruilleService d'Hématologie-Cancérologie, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
Marie-Pierre NoelService des Maladies du Sang, Hôpital Claude Huriez, Centre Regional Hospitalier Universitaire de Lille, Lille, France.
Jean-Christophe IanottoService d'Hématologie, Centre Hospitalier Universitaire Morvan, Brest, France.
Bruno VillemagneService d'Hématologie, CHD La Roche Sur Yon, La Roche-Sur-Yon, France.
Émilie CayssialsService d'Hématologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
Sophie ParkPôle de Cancérologie, Hôpital Albert Michallon, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
Philippe RousselotService d'Hématologie, Centre Hospitalier de Versailles, Université Versailles Paris-Saclay, Le Chesnay Rosquencourt, Versailles, France.
Gabriel EtienneDépartement d'Hématologie, Institut Bergonié, University of Bordeaux, INSERM, UMR1312, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The French Stop Imatinib study (STIM1) was one of the first trials to explore the possibility of discontinuing imatinib in patients with chronic myeloid leukemia (CML) who had achieved a sustained molecular response (at least a 4.5-log reduction). The stringent criteria for molecular recurrence (MRec) were defined as

Identifiers

PMID41574312
PMCPMC12820644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.